Drug Search Results

Oblimersen

Alternative Names: oblimersen, g3139
Latest Update: 2024-05-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency

Approved Indications: None

Known Adverse Events: None

Company: Genta
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oblimersen

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Melanoma|Acute Myeloid Leukemia|Lymphoid Leukemia

Phase 2: Prostate Cancer|Adenocarcinoma|Carcinoma, Merkel Cell|Melanoma|Gastrointestinal Stromal Tumors|Head and Neck Cancer|Neuroendocrine Carcinoma|Kidney Cancer|Lung Cancer|Colorectal Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Renal Cell Carcinoma|Chronic Lymphoid Leukemia|Extranodal NK-T-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Mantle-Cell Lymphoma|Bladder Cancer|Breast Cancer|Follicular Lymphoma|Esophageal Cancer|Waldenstrom Macroglobulinemia|Ovarian Cancer|Lymphoma, Non-Hodgkin|Male Breast Cancer|Chronic Myeloid Leukemia|Small Cell Lung Cancer|Squamous Cell Carcinoma|Leukemia, Plasma Cell|Lymphomatoid Granulomatosis|Burkitt Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Hepatocellular Carcinoma|Gastrointestinal Cancer|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Liver Cancer|Intraocular Lymphoma

Phase 1: Kidney Diseases|Diffuse Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Cutaneous Lymphoma|Chronic Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Lymphocytic Chronic B-Cell Leukemia|Adult T-Cell Leukemia-Lymphoma|Mantle-Cell Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Follicular Lymphoma|Small Cell Lung Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCT01200342	P2	Terminated	Melanoma	2013-09-01
0462-07-FB	P1	Terminated	Lymphoma, Non-Hodgkin\|Diffuse Large B-Cell Lymphoma	2012-10-09
NCI-2012-03134	P2	Terminated	Adenocarcinoma\|Squamous Cell Carcinoma\|Gastrointestinal Cancer\|Esophageal Cancer	2010-02-01
NCI-2011-00617	P2	Completed	B-Cell Marginal Zone Lymphoma\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Burkitt Lymphoma\|Lymphomatoid Granulomatosis\|Large-Cell Immunoblastic Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Leukemia, Plasma Cell\|Extranodal NK-T-Cell Lymphoma\|Mantle-Cell Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Lymphoid Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Adult T-Cell Leukemia-Lymphoma\|Plasmablastic Lymphoma\|Lymphoma, Non-Hodgkin\|Intraocular Lymphoma\|Diffuse Large B-Cell Lymphoma\|Waldenstrom Macroglobulinemia\|Follicular Lymphoma\|T-Cell Cutaneous Lymphoma	2010-01-01

Recent News Events

Date	Type	Title
12/20/2023	PubMed	Bcl-2 expression in cell lines breast cancer and death program.
06/13/2023	PubMed	Metal-Organic Frameworks Facilitate Nucleic Acids for Multimode Synergistic Therapy of Breast Cancer.
02/01/2023	PubMed	[Effect of erastin and G3139 on rat liver mitochondria in chronic alcoholic intoxication].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions